Bosatria mepolizumab regulatory update

FDA’s Pulmonary-Allergy Drugs Advisory Committee will meet June 11 to discuss a BLA from GlaxoSmithKline for mepolizumab as an add-on maintenance treatment in patients ages >=12 with severe eosinophil...